Study guide
20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy
Key Takeaways Explain This Topic AI
Standard treatment is rifampicin and isoniazid for six months with pyrazinamide and ethambutol for the first two months, extended to twelve months for CNS disease.
Ethambutol causes dose-related optic neuritis with red-green colour blindness; isoniazid causes peripheral neuropathy prevented by pyridoxine; pyrazinamide causes hyperuricaemia and hepatitis.
Rifampicin is a potent CYP450 inducer that turns secretions orange and renders the combined oral contraceptive ineffective.
Last updated: September 2026
- 3. Diagnostic Modalities: Active vs. Latent TB
- Microbiological Diagnostics for Active Disease
Sputum Smear Microscopy: Examination of three early morning sputum samples (including at least one supervised or induced sample via nebulised hypertonic saline). Requires a minimum of 5 , 000 – 10 , 000 bacilli/mL 5,000\text{–}10,000\text{ bacilli/mL} 5 , 000 – 10 , 000 bacilli/mL for visualization.
Ziehl-Neelsen (ZN) Stain: Acid-fast bacilli resist decolourization by acid-alcohol and retain primary carbol fuchsin, appearing as bright red beaded rods against a brilliant green or blue background.
Auramine-Rhodamine Fluorochrome Stain: Bacilli fluoresce bright yellow-green under ultraviolet microscopy; provides higher sensitivity and allows rapid scanning at lower magnification.
Mycobacterial Culture (The Gold Standard):
Solid Culture (Lowenstein-Jensen [LJ] Egg-Based Medium): Produces characteristic rough, buff, crumbly colonies; requires 4 to 8 weeks due to slow mycobacterial doubling time (18–24 hours).
Automated Liquid Culture (Bactec MGIT [Mycobacteria Growth Indicator Tube]): Detects mycobacterial oxygen consumption fluorometrically; significantly faster turnaround time ( 1 to 3 weeks ). Enables phenotypic drug susceptibility testing (DST) against first- and second-line antimicrobials.
GeneXpert MTB/RIF (Nucleic Acid Amplification Test [NAAT]):
An automated, cartridge-based real-time PCR assay endorsed by the World Health Organization and NICE.
Simultaneously amplifies M. tuberculosis complex DNA and detects point mutations in the r p o B rpoB r p o B gene (the RNA polymerase beta-subunit gene responsible for > 95 % > 95\% > 95% of rifampicin resistance ).
Delivers results within 2 hours with high sensitivity ( > 98 % > 98\% > 98% in smear-positive cases) and serves as an early surrogate marker for multidrug-resistant TB (MDR-TB, defined as resistance to at least both rifampicin and isoniazid).
Latent TB Screening: Mantoux Test vs. IGRA
Diagnostic Feature Tuberculin Skin Test (TST / Mantoux) Interferon-Gamma Release Assay (IGRA)
Biological Principle In vivo delayed-type (Type IV) cell-mediated hypersensitivity reaction to Purified Protein Derivative (PPD) Ex vivo quantification of IFN- γ \gamma γ released by sensitized T-lymphocytes upon exposure to specific antigens
Specific Antigens Used Crude cocktail of > 200 > 200 > 200 shared mycobacterial proteins (PPD) Highly specific recombinant M. tuberculosis antigens: ESAT-6 and CFP-10 (and TB7.7)
Effect of Prior BCG Vaccination Frequent false-positive results (BCG strain M. bovis shares many PPD antigens) Zero cross-reactivity with BCG ; entirely unaffected by prior BCG vaccination status
Non-Tuberculous Mycobacteria (NTM) Frequent false-positives from environmental NTM exposure Negative in most environmental NTM infections (except M. kansasii , M. marinum , M. szulgai )
Logistical Requirements Requires intradermal forearm injection; patient must return strictly at 48 to 72 hours for induration measurement Single venepuncture blood test (QuantiFERON-TB Gold Plus or T-SPOT.TB); requires no return visit
Reading Metric Transverse diameter of palpable induration (not erythema): ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm (immunosuppressed/HIV), ≥ 10 mm \ge 10\text{ mm} ≥ 10 mm (high-risk), ≥ 15 mm \ge 15\text{ mm} ≥ 15 mm (general) Automated laboratory ELISA (optical density) or ELISpot (enumerating IFN- γ \gamma γ spot-forming cells)
UK Guidelines (NICE) Second-line or in young children First-line screening modality for LTBI in adults, healthcare workers, contacts, and prior to anti-TNF initiation
- 4. Anti-Tuberculous Pharmacotherapy (BTS & NICE Guidelines)
- Standard Regimen for Active Drug-Susceptible Pulmonary Tuberculosis
Standard treatment consists of a 6-month short-course regimen combining four bactericidal and sterilizing agents, categorized into two distinct phases to suppress rapid mutational resistance:
Initial Intensive Phase (2 Months): Quadruple therapy with Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol (RIPE) . Rapidly reduces the mycobacterial load and prevents the emergence of drug-resistant mutants.
Continuation Phase (4 Months): Dual therapy with Rifampicin and Isoniazid (RH) . Eliminates slow-replicating semi-dormant 'persister' bacilli within necrotic lesions, preventing late relapse.
Special Treatment Durations & Corticosteroid Indications
Central Nervous System (Tuberculous Meningitis): Extended to a 12-month total course (2 months RIPE followed by 10 months RH). Adjunctive systemic dexamethasone ( 0.4 mg/kg/day 0.4\text{ mg/kg/day} 0.4 mg/kg/day tapered over 6 to 8 weeks) is mandatory; it reduces mortality by 30 % 30\% 30% by attenuating cerebral vasculitis and basal exudate inflammation.
Tuberculous Pericarditis: Standard 6-month antimicrobial course plus adjunctive oral prednisolone tapered over 6 weeks to reduce the incidence of constrictive pericarditis and pericardiectomy.
Osteoarticular Tuberculosis: 6 to 9 months depending on clinical and radiological response.
Comprehensive Drug Mechanisms, Toxicities & Monitoring
First-Line Agent Mechanism of Action & Resistance Gene Classical Adverse Effects & Toxicities Clinical Management & Monitoring Mandates
Rifampicin (R) Inhibits DNA-dependent RNA polymerase by binding beta-subunit; resistance via rpoB gene mutations • Potent hepatic CYP450 enzyme inducer (CYP3A4, 2C9, 2C19); • Harmless orange-red discolouration of urine, tears, saliva, sweat, and soft contact lenses; • Cholestatic/hepatocellular hepatotoxicity; • Acute interstitial nephritis, thrombocytopenic purpura, flu-like syndrome Dramatically lowers circulating serum concentrations of warfarin, direct oral anticoagulants, oral contraceptives (must use barrier contraception), antiretrovirals, anticonvulsants, and corticosteroids. Baseline and monthly LFTs.
Isoniazid (H) Inhibits mycolic acid synthesis via inhibition of NADH-dependent enoyl-ACP reductase; resistance via katG (catalase-peroxidase) or inhA promoter mutations • Dose-dependent peripheral neuropathy (interferes with pyridoxine / vitamin B6 metabolism); • Hepatotoxicity (transaminitis; metabolite acetylhydrazine); • Drug-induced lupus erythematosus (anti-histone antibodies positive); • Sideroblastic anaemia, agranulocytosis Mandatory co-prescription of Pyridoxine (Vitamin B6) 10 mg 10\text{ mg} 10 mg daily in all patients at risk of neuropathy (diabetes, alcohol misuse, CKD, malnutrition, pregnancy, HIV). Stop if transaminases exceed 5 × 5\times 5 × normal (or 3 × 3\times 3 × if symptomatic).
Pyrazinamide (Z) Converted to active pyrazinoic acid by bacterial pyrazinamidase (encoded by pncA ); disrupts cell membrane potential and transport • Hyperuricaemia (inhibits renal tubular urate excretion; precipitates acute gout and arthralgia); • Most hepatotoxic first-line agent ; • Cutaneous photosensitivity, gastrointestinal upset Monitor serum uric acid. Treat mild non-gouty arthralgias symptomatically with NSAIDs without discontinuing drug; discontinue if acute podagra/gout or severe hepatitis develops.
Ethambutol (E) Inhibits arabinosyl transferase (encoded by embB ), halting synthesis of cell wall arabinogalactan • Retrobulbar optic neuritis (dose- and duration-dependent demyelinating optic neuropathy); • Earliest clinical sign: loss of red-green colour discrimination ; • Reduced visual acuity, central scotoma Mandatory baseline testing of visual acuity (Snellen chart) and colour vision (Ishihara plates) prior to initiation. Excreted renally: requires mandatory dose adjustment in renal failure. Advise immediate cessation if visual symptoms occur.